Cdt1
Cdt1[edit | edit source]
Cdt1 (Chromatin licensing and DNA replication factor 1) is a crucial protein involved in the regulation of DNA replication in eukaryotic cells. It plays a significant role in ensuring that the genome is replicated precisely once per cell cycle, thus maintaining genomic stability.
Function[edit | edit source]
Cdt1 is a key component of the pre-replication complex (pre-RC), which assembles at the origins of replication during the G1 phase of the cell cycle. It works in conjunction with other proteins such as Cdc6 and the origin recognition complex (ORC) to load the MCM complex (minichromosome maintenance complex) onto DNA, a critical step in the initiation of DNA replication.
Regulation[edit | edit source]
The activity of Cdt1 is tightly regulated to prevent re-replication of DNA within a single cell cycle. This regulation is achieved through several mechanisms:
- Proteolysis: Cdt1 is targeted for degradation by the ubiquitin-proteasome system during the S phase and G2 phase of the cell cycle. This degradation is mediated by the SCF complex and the CRL4 complex, which ubiquitinate Cdt1, marking it for destruction.
- Inhibition by Geminin: Cdt1 is also inhibited by the protein Geminin, which binds to Cdt1 and prevents it from loading the MCM complex onto DNA. Geminin levels are high during the S, G2, and M phases, ensuring that Cdt1 is inactive during these phases.
- Phosphorylation: Cdt1 can be phosphorylated by various kinases, which can alter its activity and stability.
Clinical Significance[edit | edit source]
Dysregulation of Cdt1 can lead to genomic instability, which is a hallmark of cancer. Overexpression of Cdt1 has been observed in several types of cancer, and it is thought to contribute to oncogenesis by promoting DNA re-replication and genomic instability. Conversely, loss of Cdt1 function can lead to cell cycle arrest and apoptosis.
Research[edit | edit source]
Ongoing research is focused on understanding the precise molecular mechanisms by which Cdt1 is regulated and how its dysregulation contributes to disease. There is also interest in targeting the Cdt1 regulatory pathway for cancer therapy.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
